 |
PDBsum entry 7dcc
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Viral protein
|
PDB id
|
|
|
|
7dcc
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
221 a.a.
|
|
|
|
|
|
|
|
|
|
|
1061 a.a.
|
|
|
|
|
|
|
|
|
|
|
213 a.a.
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Viral protein
|
|
|
Title:
|
|
S-3c1-f3b structure, all the three rbds are in the up conformation and each of them associates with a 3c1 fab
|
|
Structure:
|
|
The heavy chain of 3c1 fab. Chain: a, b, d. Spike glycoprotein. Chain: e, i, k. Synonym: s glycoprotein,e2,peplomer protein,sarc-cov2 s protein. Engineered: yes. The light chain of 3c1 fab. Chain: f, h, m
|
|
Source:
|
|
Mus musculus. Organism_taxid: 10090. Strain: balb/c. Severe acute respiratory syndrome coronavirus 2. 2019-ncov. Organism_taxid: 2697049. Gene: s, 2. Expressed in: homo sapiens.
|
|
Authors:
|
|
Y.Cong,C.X.Liu
|
|
Key ref:
|
|
C.Zhang
et al.
(2021).
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
Nat Commun,
12,
264.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
24-Oct-20
|
Release date:
|
02-Dec-20
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Nat Commun
12:264
(2021)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
|
|
C.Zhang,
Y.Wang,
Y.Zhu,
C.Liu,
C.Gu,
S.Xu,
Y.Wang,
Y.Zhou,
Y.Wang,
W.Han,
X.Hong,
Y.Yang,
X.Zhang,
T.Wang,
C.Xu,
Q.Hong,
S.Wang,
Q.Zhao,
W.Qiao,
J.Zang,
L.Kong,
F.Wang,
H.Wang,
D.Qu,
D.Lavillette,
H.Tang,
Q.Deng,
Y.Xie,
Y.Cong,
Z.Huang.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies
against SARS-CoV-2 are an option for drug development for treating COVID-19.
Here, we report the identification and characterization of two groups of mouse
neutralizing monoclonal antibodies (MAbs) targeting the receptor-binding domain
(RBD) on the SARS-CoV-2 spike (S) protein. MAbs 2H2 and 3C1, representing the
two antibody groups, respectively, bind distinct epitopes and are compatible in
formulating a noncompeting antibody cocktail. A humanized version of the 2H2/3C1
cocktail is found to potently neutralize authentic SARS-CoV-2 infection in vitro
with half inhibitory concentration (IC50) of 12 ng/mL and effectively treat
SARS-CoV-2-infected mice even when administered at as late as 24 h
post-infection. We determine an ensemble of cryo-EM structures of 2H2 or 3C1 Fab
in complex with the S trimer up to 3.8 Å resolution, revealing the
conformational space of the antigen-antibody complexes and MAb-triggered
stepwise allosteric rearrangements of the S trimer, delineating a previously
uncharacterized dynamic process of coordinated binding of neutralizing
antibodies to the trimeric S protein. Our findings provide important information
for the development of MAb-based drugs for preventing and treating SARS-CoV-2
infections.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
| |
Links
